Document is current

Article History

Received: 29 January 2024

Accepted: 9 July 2025

First Online: 20 August 2025

Competing interests

: O.L. has received research funding from NIH, NCI, U.S. Food and Drug Administration, MMRF, International Myeloma Foundation, LLS, Myeloma Solutions Fund, Paula and Rodger Riney Multiple Myeloma Research Program Fund, the Tow Foundation, Perelman Family Foundation, Rising Tide Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, Karyopharm; Honoraria/ad boards: Adaptive, Amgen, Binding Site, Bristol Myers Squibb (BMS), Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer; and serves on Independent Data Monitoring Committees for clinical trials lead by Takeda, Merck, Janssen, Theradex. G.J.M. has received funding from NIH, NCI, MMRF, LLS, Perelman Family Foundation, Amgen, Celgene, Janssen and Takeda; has received honoraria or advisory board fees from Adaptive, Amgen, BMS, Celgene and Janssen; and serves on Independent Data Monitoring Committees for clinical trials led by Takeda, Karyopharm and Sanofi. E.K.M. reports consulting or advisory role, honoraria, research funding, travel accommodation and expenses from BMS (Celgene), GlaxoSmithKline (GSK), Janssen-Cilag, Oncopeptides, Pfizer, Sanofi, Stemline and Takeda. K.C.W. reports research grant from AbbVie, Amgen, BMS/Celgene, Janssen, GSK and Sanofi; and has received honoraria and consulting fees from AbbVie, Amgen, Adaptive Biotech, AstraZeneca, BMS/Celgene, BeiGene, Janssen, GSK, Karyopharm, Novartis, Oncopeptides, Pfizer, Roche Pharma, Sanofi, Stemline and Takeda. R.F. reports consulting or advisory role, honoraria, travel accommodation and expenses from Amgen, BMS (Celgene), GSK, Janssen-Cilag, Sanofi, Stemline and Takeda. K.H.S. has served on an advisory board for AbbVie, Amgen, BMS, GSK and Janssen; received honoraria for Adaptive Biotechnologies Corporation, Amgen, BMS, GSK, Janssen and Sanofi Genzyme; and has received research funding from AbbVie and Karyopharm Therapeutics. H.G. has received grants and/or provision of investigational medicinal product from BMS/Celgene, Dietmar-Hopp-Foundation, Janssen and Sanofi; research support from Amgen, BMS, Celgene, GlycoMimetics, GSK, Heidelberg Pharma, Hoffmann-La Roche, Janssen, Millenium Pfizer, Sanofi and Novartis; advisory board fees from BMS, GSK, Janssen and Sanofi; honoraria from Amgen, BMS, GSK, Janssen, Oncopeptides, Sanofi and Pfizer; and support for attending meetings and/or travel form Amgen, BMS, GSK, Janssen, Oncopeptides, Sanofi and Pfizer. N.K. has received research funding from Janssen and AbbVie, and has served on an advisory board for Janssen. K.H.M. has received funding from the Multiple Myeloma Research Foundation, the American Society of Hematology and the IMS. L.B.B. served as a consultant for Genentech. F.M. has received consulting fees from Medidata and Sanofi. B.D. reports consulting via an independent data review committee for Janssen. All other authors declare no competing interests.